Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
53 hedge funds and large institutions have $55.6M invested in Cidara Therapeutics in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 6 reducing their positions, and 8 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 6
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
6% more funds holding
Funds holding: 50 → 53 (+3)
0.27% more ownership
Funds ownership: 2.5% → 2.77% (+0.27%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
12% less capital invested
Capital invested by funds: $63.3M → $55.6M (-$7.69M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$3.41M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.71M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.75M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$477K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$339K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$171K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$152K |
| 5 |
Millennium Management
New York
|
-$123K |
CDTX Hedge Fund Activity: Q1 2020 in Review
53 of the 4,546 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q1 2020, worth a combined $55.6M — down 12% from $63.3M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CDTX positions and 8 closed out — a net gain of 4 holders — while 30 added to existing stakes and 6 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.9M. The largest seller was Raymond James Financial Services Advisors, exiting entirely with an estimated $477K sold.
- 53 institutional investors held Cidara Therapeutics (CDTX) as of Q1 2020, up from 50 in Q4 2019.
- Funds reported $55.6M of Cidara Therapeutics stock for Q1 2020, down 12% quarter-over-quarter.
- 12 funds opened new Cidara Therapeutics positions in Q1 2020 and 8 closed out, a net change of +4 holders.
- The largest Cidara Therapeutics buyer in Q1 2020 was Stonepine Capital Management, an estimated $3.9M added.
- The largest Cidara Therapeutics seller in Q1 2020 was Raymond James Financial Services Advisors, an estimated $477K sold.
Based on aggregated 13F filings for Q1 2020.